Cite
HARVARD Citation
Bossuyt, P. et al. (2022). Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial. Journal of Crohn's and colitis. pp. 199-206. [Online].